Literature DB >> 30302036

L-Ornithine L-Aspartate is Effective and Safe for the Treatment of Hepatic Encephalopathy in Cirrhosis.

Sandeep S Sidhu1.   

Abstract

Entities:  

Year:  2018        PMID： 30302036      PMCID： PMC6175754          DOI： 10.1016/j.jceh.2018.08.007

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  26 in total

1.  Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.

Authors:  Shahab Abid; Wasim Jafri; Khalid Mumtaz; Muhammad Islam; Zaigham Abbas; Hasnain Ali Shah; Saeed Hamid
Journal:  J Coll Physicians Surg Pak       Date:  2011-11       Impact factor: 0.711

Review 2.  Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.

Authors:  Lise L Gluud; Hendrik Vilstrup; Marsha Y Morgan
Journal:  Hepatology       Date:  2016-05-20       Impact factor: 17.425

Review 3.  Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.

Authors:  G-Q Zhu; K-Q Shi; S Huang; L-R Wang; Y-Q Lin; G-Q Huang; Y-P Chen; M Braddock; M-H Zheng
Journal:  Aliment Pharmacol Ther       Date:  2015-02-13       Impact factor: 8.171

Review 4.  Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.

Authors:  J S Bajaj; J Cordoba; K D Mullen; P Amodio; D L Shawcross; R F Butterworth; M Y Morgan
Journal:  Aliment Pharmacol Ther       Date:  2011-02-09       Impact factor: 8.171

5.  Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.

Authors:  J S Bajaj; A J Sanyal; D Bell; H Gilles; D M Heuman
Journal:  Aliment Pharmacol Ther       Date:  2010-02-05       Impact factor: 8.171

Review 6.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

7.  L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.

Authors:  Qian Jiang; Xue-Hua Jiang; Ming-Hua Zheng; Yong-Ping Chen
Journal:  J Gastroenterol Hepatol       Date:  2008-09-24       Impact factor: 4.029

Review 8.  Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.

Authors:  Roger F Butterworth; Ali Canbay
Journal:  Dig Dis       Date:  2018-07-17       Impact factor: 2.404

9.  Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis.

Authors:  Dong Wu; Shu-Mei Wu; Jie Lu; Ying-Qun Zhou; Ling Xu; Chuan-Yong Guo
Journal:  Gastroenterol Res Pract       Date:  2013-04-03       Impact factor: 2.260

Review 10.  L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Authors:  Ee Teng Goh; Caroline S Stokes; Sandeep S Sidhu; Hendrik Vilstrup; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.